The JNJ-ARGX deal in MDS/AML

Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
Post Reply
cheng_ho
Posts: 202
Joined: Sun Apr 03, 2016 11:27 pm

The JNJ-ARGX deal in MDS/AML

Post by cheng_ho » Fri Feb 22, 2019 10:03 pm

is there anyone who has looked at the ARGX MDS trial that doesn't think that this is why JNJ dropped imet?

https://www.argenx.com/en-GB/news-inter ... mia/30208/

So the question now is which direction GERN should go.

karagozoglu12345
Posts: 61
Joined: Wed Oct 03, 2018 12:48 am

Re: The JNJ-ARGX deal in MDS/AML

Post by karagozoglu12345 » Sat Feb 23, 2019 10:06 pm

Argx drug targets high risk MDS whereas Imet targets intermediate-1 or low risk patient groups. However, phenomonal success of their drug in AML may be a significant threat to Geron's future attempt to widen the scope of treatment space to include AML.

Post Reply